S&P 500   3,973.46 (-0.73%)
DOW   32,280.73 (-0.86%)
QQQ   309.96 (-0.12%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.15 (+0.22%)
AMZN   100.21 (-0.40%)
TSLA   194.64 (-1.49%)
NVDA   270.17 (+3.12%)
NIO   9.23 (-0.43%)
BABA   84.28 (+0.69%)
AMD   99.06 (+3.26%)
T   18.54 (+0.00%)
F   11.68 (-0.34%)
MU   59.02 (+0.67%)
CGC   1.92 (-2.79%)
GE   90.81 (-1.49%)
DIS   96.20 (-0.35%)
AMC   4.52 (+2.49%)
PFE   40.25 (-1.01%)
PYPL   75.39 (-1.73%)
NFLX   298.36 (-2.43%)
S&P 500   3,973.46 (-0.73%)
DOW   32,280.73 (-0.86%)
QQQ   309.96 (-0.12%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.15 (+0.22%)
AMZN   100.21 (-0.40%)
TSLA   194.64 (-1.49%)
NVDA   270.17 (+3.12%)
NIO   9.23 (-0.43%)
BABA   84.28 (+0.69%)
AMD   99.06 (+3.26%)
T   18.54 (+0.00%)
F   11.68 (-0.34%)
MU   59.02 (+0.67%)
CGC   1.92 (-2.79%)
GE   90.81 (-1.49%)
DIS   96.20 (-0.35%)
AMC   4.52 (+2.49%)
PFE   40.25 (-1.01%)
PYPL   75.39 (-1.73%)
NFLX   298.36 (-2.43%)
S&P 500   3,973.46 (-0.73%)
DOW   32,280.73 (-0.86%)
QQQ   309.96 (-0.12%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.15 (+0.22%)
AMZN   100.21 (-0.40%)
TSLA   194.64 (-1.49%)
NVDA   270.17 (+3.12%)
NIO   9.23 (-0.43%)
BABA   84.28 (+0.69%)
AMD   99.06 (+3.26%)
T   18.54 (+0.00%)
F   11.68 (-0.34%)
MU   59.02 (+0.67%)
CGC   1.92 (-2.79%)
GE   90.81 (-1.49%)
DIS   96.20 (-0.35%)
AMC   4.52 (+2.49%)
PFE   40.25 (-1.01%)
PYPL   75.39 (-1.73%)
NFLX   298.36 (-2.43%)
S&P 500   3,973.46 (-0.73%)
DOW   32,280.73 (-0.86%)
QQQ   309.96 (-0.12%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.15 (+0.22%)
AMZN   100.21 (-0.40%)
TSLA   194.64 (-1.49%)
NVDA   270.17 (+3.12%)
NIO   9.23 (-0.43%)
BABA   84.28 (+0.69%)
AMD   99.06 (+3.26%)
T   18.54 (+0.00%)
F   11.68 (-0.34%)
MU   59.02 (+0.67%)
CGC   1.92 (-2.79%)
GE   90.81 (-1.49%)
DIS   96.20 (-0.35%)
AMC   4.52 (+2.49%)
PFE   40.25 (-1.01%)
PYPL   75.39 (-1.73%)
NFLX   298.36 (-2.43%)
NASDAQ:LNTH

Lantheus - LNTH Stock Forecast, Price & News

$81.76
-1.10 (-1.33%)
(As of 03/22/2023 03:25 PM ET)
Add
Compare
Today's Range
$81.36
$83.54
50-Day Range
$50.04
$82.86
52-Week Range
$47.46
$87.47
Volume
669,064 shs
Average Volume
1.03 million shs
Market Capitalization
$5.52 billion
P/E Ratio
240.47
Dividend Yield
N/A
Price Target
$107.33

Lantheus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
30.1% Upside
$107.33 Price Target
Short Interest
Bearish
5.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.39mentions of Lantheus in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$11.50 M Sold Last Quarter
Proj. Earnings Growth
17.71%
From $4.46 to $5.25 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

101st out of 983 stocks

Diagnostic Substances Industry

1st out of 14 stocks


LNTH stock logo

About Lantheus (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in Bedford, MA.

Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Stock News Headlines

Are These Medical Device Makers Getting Ready To Rally? (LNTH)
Current trends and changing demographics are behind growth of medical technology companies. An aging population and a shift to in-home care are among factors.
This Trade Strategy Outpaces Almost Anything
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Lantheus Announces Two Key Executive Promotions
How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Bull of the Day: Lantheus (LNTH)
Why Shares of Lantheus Holdings Rose This Week
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Company Calendar

Last Earnings
2/23/2023
Today
3/22/2023
Next Earnings (Estimated)
5/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LNTH
Employees
612
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$107.33
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$91.00
Forecasted Upside/Downside
+29.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$28.07 million
Pretax Margin
2.86%

Debt

Sales & Book Value

Annual Sales
$935.06 million
Cash Flow
$5.04 per share
Book Value
$6.50 per share

Miscellaneous

Free Float
66,459,000
Market Cap
$5.60 billion
Optionable
Optionable
Beta
0.64

Key Executives

  • Mary Anne HeinoMary Anne Heino
    President, Chief Executive Officer & Director
  • Paul BlanchfieldPaul Blanchfield
    Chief Operating Officer
  • Robert J. MarshallRobert J. Marshall
    Chief Financial Officer & Treasurer
  • Simon Robinson
    Senior VP-Research & Pharmaceutical Development
  • Iryna Teslenko
    Vice President-Clinical Development













LNTH Stock - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price objectives for Lantheus' shares. Their LNTH share price forecasts range from $91.00 to $120.00. On average, they expect the company's share price to reach $107.33 in the next year. This suggests a possible upside of 29.5% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2023?

Lantheus' stock was trading at $50.96 on January 1st, 2023. Since then, LNTH stock has increased by 62.6% and is now trading at $82.86.
View the best growth stocks for 2023 here
.

Are investors shorting Lantheus?

Lantheus saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 3,720,000 shares, an increase of 32.9% from the February 13th total of 2,800,000 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is currently 3.3 days. Approximately 5.6% of the company's shares are short sold.
View Lantheus' Short Interest
.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our LNTH earnings forecast
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its earnings results on Thursday, February, 23rd. The medical equipment provider reported $1.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.87 by $0.41. The medical equipment provider had revenue of $263.17 million for the quarter, compared to the consensus estimate of $244.61 million. Lantheus had a net margin of 3.00% and a trailing twelve-month return on equity of 51.60%.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its first quarter 2023 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of $1.28-$1.32 for the period, compared to the consensus EPS estimate of $1.06. The company issued revenue guidance of $280.00 million-$285.00 million, compared to the consensus revenue estimate of $253.59 million.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (4.64%), Dimensional Fund Advisors LP (2.10%), Geode Capital Management LLC (1.89%), Silvercrest Asset Management Group LLC (1.63%), T. Rowe Price Investment Management Inc. (1.54%) and Price T Rowe Associates Inc. MD (1.51%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends
.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $82.86.

How much money does Lantheus make?

Lantheus (NASDAQ:LNTH) has a market capitalization of $5.60 billion and generates $935.06 million in revenue each year. The medical equipment provider earns $28.07 million in net income (profit) each year or $0.34 on an earnings per share basis.

How many employees does Lantheus have?

The company employs 612 workers across the globe.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860.

This page (NASDAQ:LNTH) was last updated on 3/22/2023 by MarketBeat.com Staff